Pancreatic Neuroendocrine Tumors (Islet Cell Tumors): Symptoms, Diagnosis, and Genetic Insights
At a Glance
- Sample Required: Blood or saliva (for genetic testing)
- Fasting Rules: Not required for genetic testing; may be required for hormone assays
- Turnaround Time (TAT): 7–10 working days
- Base Cost: [Insert Current 2026 Price]
Understanding Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumors (NETs), also known as islet cell tumors, are a rare but clinically significant group of neoplasms arising from the hormone-producing cells of the pancreas. These tumors can be functional (secreting excess hormones) or non-functional (not causing hormonal symptoms). While they often grow slowly, early detection is critical for optimal management.
Clinical Presentation and Symptom Patterns
Symptoms vary depending on the tumor type and hormone secretion. The table below outlines common functional NETs and their associated symptoms.
| Tumor Type | Hormone Overproduction | Common Symptoms |
|---|---|---|
| Insulinoma | Insulin | Hypoglycemia, shakiness, sweating, confusion, palpitations |
| Gastrinoma | Gastrin | Peptic ulcers, abdominal pain, diarrhea, GERD |
| Glucagonoma | Glucagon | Necrolytic migratory erythema, weight loss, diabetes, anemia |
| VIPoma | Vasoactive intestinal peptide | Watery diarrhea, hypokalemia, achlorhydria (WDHA syndrome) |
| Somatostatinoma | Somatostatin | Diabetes, gallstones, steatorrhea, weight loss |
Non-Functional NETs
Non-functional tumors do not secrete hormones but may cause symptoms due to mass effect: abdominal pain, jaundice, palpable mass, or weight loss. These are often diagnosed incidentally on imaging.
Diagnostic Modalities and Genetic Testing
Diagnosis involves biochemical testing (e.g., chromogranin A, specific hormone levels), imaging (CT, MRI, somatostatin receptor scintigraphy), and histopathology. For hereditary cases, genetic testing is essential.
Role of Next-Generation Sequencing (NGS)
DNA Labs India offers comprehensive NGS-based panels for hereditary pancreatic NET syndromes, including MEN1, VHL, and NF1. Whole Exome Sequencing (WES) may be recommended when the clinical picture is ambiguous. Genetic testing helps identify at-risk family members and guides surveillance.
| Test | Purpose | Sample | TAT |
|---|---|---|---|
| Hereditary NET Panel (NGS) | Detects germline mutations in MEN1, VHL, NF1, etc. | Blood or saliva | 7–10 working days |
| Whole Exome Sequencing | Comprehensive analysis of all coding regions | Blood | 14–21 working days |
Treatment Landscape and Prognosis
Management depends on tumor grade, stage, and functionality. Options include surgical resection, somatostatin analogs, peptide receptor radionuclide therapy (PRRT), chemotherapy, and targeted therapies. Early-stage NETs have a favorable prognosis, with 5-year survival exceeding 80% for localized disease.
When to Seek Medical Attention
If you experience persistent unexplained symptoms such as recurrent hypoglycemia, refractory peptic ulcers, chronic diarrhea, or skin rashes, consult a physician promptly. Early referral to a specialist and genetic counseling can significantly impact outcomes.
Frequently Asked Questions
Are pancreatic NETs hereditary?
About 10% of pancreatic NETs are associated with inherited syndromes like MEN1, VHL, and NF1. Genetic testing is recommended for individuals with a family history or multiple tumors.
What is the difference between a pancreatic NET and pancreatic adenocarcinoma?
NETs arise from neuroendocrine cells and are generally less aggressive than adenocarcinoma, which originates from exocrine cells. Treatment and prognosis differ significantly.
Written by: Dr. Ananya Sharma, MBBS, MD (Internal Medicine)
Medically Reviewed by: Dr. Rajesh Kumar, DM (Medical Oncology)
Last Updated: February 2026
Lab Certification: DNA Labs India is an ISO 9001 certified laboratory.